Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis

Thrombosis Research

Volumn 118, Issue 6, 2006, Pages 747-753

  Lewis, Deborah A ^a   Nyska, Abraham ^b   Potti, Anil ^a   Hoke, Heather A ^a   Klemp, Keith F ^a   Ward, Sandra M ^b   Peddada, Shyamal D ^b   Wu, Jogin ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

2 butoxyethanol; Animal models; Hemolysis; Microvascular thrombosis; Sickle cell disease

Indexed keywords

2 BUTOXYETHANOL; ANTITHROMBIN III; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BONE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE COUNT; EYE; FEMALE; HEMOLYSIS; HEMOSTASIS; INTRACARDIAC THROMBOSIS; LIVER; LUNG; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTHROMBIN TIME; RAT; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANEMIA, HEMOLYTIC; ANEMIA, SICKLE CELL; ANIMALS; ANTITHROMBIN III; BETA-THALASSEMIA; BIOLOGICAL MARKERS; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERYTHROCYTE AGGREGATION; ETHYLENE GLYCOLS; FEMALE; HEMOLYSIS; HEMOSTASIS; INTERCELLULAR ADHESION MOLECULE-1; PEPTIDE HYDROLASES; RATS; RATS, INBRED F344; THROMBOSIS;

EID: 33750455496     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.11.010     Document Type: Article

References (33)

1. Gibson T. A market analysis of 2-butoxyethanol and 2-butoxyethylacetate. Prepared for the US Environmental Protection Agency, Regulatory Impact Branch, subcontract EPA 36-5 of ICF, Inc. (1984) contract no. 68-02-4055
2. Ghanayem B.I., Ward S.M., Blair P.C., and Matthews H.B. Comparison of the hematological effects of 2-butoxyethanol using two types of hematology analyzers. Toxicol Appl Pharmacol 106 (1990) 341-345
3. Udden M.M. Rat erythocyte morphological changes after gavage dosing with 2-butoxyethanol: a comparison with the invitro effects of butoxyacetic acid on rat and human. J Appl Toxicol 20 (2000) 381-387
4. Ghanayem B.I., Ward S.M., Chanas B., and Nyska A. Comparison of the acute hematotoxicity of 2-butoxyethanol in male and female F344 rats. Hum Exp Toxicol 19 (2000) 185-192
5. Program N.T. Toxicology and carcinogenesis studies of 2-butoxyethanol (CAS no. 111-76-2) in F344/N rats and B6C3F1 mice (inhalation studies) Technical Report Series 484, Health and Human Services (1998), Public Health Service, Bethesda, MD
6. Long P.H., Maronpot R.R., Ghanayem B.I., Roycroft J.H., and Nyska A. Dental pulp infarction in female rats following inhalation exposure to 2-butoxyethanol. Toxicol Pathol 28 (2000) 246-252
7. Nyska A., Maronpot R., Long P., Hailey R., Travos G., Roycroft J., et al. Disseminated thrombosis and bone infarction in female rats following inhalation exposure to 2-butoxyethanol. Toxicol Pathol 27 (1999) 287-294
8. Nyska A., Maronpot R.R., and Ghanayem B.I. Ocular thrombosis and retinal degeneration induced in female F344 rats by 2-butoxyethanol. Hum Exp Toxicol 18 (1999) 577-582
9. Koshkaryev A., Barshtein G., Nyska A., Ezov N., Levin-Harrus T., Shabat S., et al. 2-Butoxyethanol enhances the adherence of red blood cells. Arch Toxicol 77 (2003) 465-469
10. Nyska A., Moomaw C.R., Ezov N., Shabat S., Levin-Harrus T., Nyska M., et al. Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2 butoxyethanol-induced hemolysis and thrombosis in female rats. Exp Toxicol Pathol 55 (2003) 231-236
11. Beutler E. The sickle cell diseases and related disorders. In: Wonsiewicz M., and Edmonson K.G. (Eds). Williams Hematology (2001), McGraw-Hill 581-605
12. Parise L., and Telen M. Erythrocyte adhesion in sickle cell disease. Current Hematol Rep 2 (2003) 102-108
13. Eldor A., and Rachmilewitz E.A. The hypercoagulable state in thalassemia. Blood 99 (2002) 36-43
14. Paszty C., Brion C.M., Manci E., Witkowska H.E., Stevens M.E., Mohandas N., et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278 (1997) 876-878
15. 0-thalassemia. Proc Natl Acad Sci 92 (1995) 11608-11612
16. Nagel R.L., and Fabry M.E. The panoply of animal models for sickle cell anaemia. Br J Haematol 112 (2001) 19-25
17. Aster J.C. Red blood cell and bleeding disorders. In: Kumar V., Abbas A., and Fausto N. (Eds). Robbins and Cotran: Pathological Basis of Disease (2004), Elsevier 619-660
18. Westerman M., Green D., Gilman-Sachs A., Beaman K., Freels S., Boggio L., et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle disease. J Lab Clin Med 134 (1999) 352-362
19. Hagger D., S.W., Owen J., and Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy Black controls. Blood Coagul Fibrinolysis 6 (1995) 93-99
20. Francis R.B.J. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2 (1991) 341-353
21. In: Grossblatt N. (Ed). Guide for the care and use of laboratory animals (1996), National Academy Press
22. Ravanat C., Freund M., Dol F., Cadroy Y., Roussi J., Incardona F., et al. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis 6 (1995) 446-455
23. Chhabra R.S., Huff J.E., Schwartz B.S., and Selkirk J. An overview of prechronic and chronic toxicity/carcinogenicity experimental study designs and criteria used by the National Toxicology Program. Health Perspect 86 (1990) 313-321
24. Ezov N., Levin-Harrus T., Mittelman M., Redlich M., Shabat S., and Ward S.M. A chemically induced rat model of hemolysis with disseminated thrombosis. Cardiovasc Toxicol 2 (2002) 181-194
25. Conran N., Fattori A., Saad S.T.O., and Costa F.F. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am J Hematol 76 (2004) 343-347
26. Gladwin M.T., Shelhamer J.H., Ognibene Fp., Pease-Fye M.E., Nichols J.S., Link B., et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 116 (2002) 436-444
27. Babiker M.A., Ashong E.F., Bahakim H., and Gader A.M. Coagulation changes in sickle cell disease in early childhood. Acta Haematol 77 (1987) 156-160
28. Caocci L., Alberti M., Burrai P., and Corda R. Screening coagulation tests and clotting factors in homozygous beta-thalassemia. Acta Haematol 66 (1978) 358-364
29. Kyriakou D.S., Alexandrakis M.G., Kyriakou E.S., Liapi D., Kourelis T.V., Passam F., et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 80 (2001) 577-583
30. Asakura H., Suga Y., Aoshima K., Ontachi Y., Mizutani T., Kato M., et al. Marked difference in pathophysiology between tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation models in rats. Crit Care Med 30 (2002) 161-164
31. Taylor M.C., WIlliams J.M., Lote C.J., Howie A.J., Thewles A., Wood J.A., et al. A laboratory model of toxin-induced hemolytic uremic syndrome. Kidney Int 55 (1999) 1336-1374
32. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. New Engl J Med 332 (1995) 1317-1322
33. Weiner D.L., Hibberd P.L., Betit P., Cooper A.B., Botelho C.A., and Brugnara C. Preliminary Assessment of Inhaled Nitric Oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 289 (2003) 1136-1142